Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines

STAT, December 11, 2017
Ed Silverman, quoting I. Glenn Cohen (Faculty Director)

From the article: Unfortunately, there are indications that the company, which could use a blockbuster product, should have taken its corporate foot off the gas pedal.  And to restore confidence in vaccines, a reckoning is required. …

Read More

2017’s Word Of The Year In Health Law And Bioethics: Uncertainty

Health Affairs, December 8, 2017
Carmel Shachar (Executive Director) and I. Glenn Cohen (Faculty Director)

Note: This post is the first in a series of Health Affairs posts from the Sixth Annual Health Law Year in P/Review event, held…

Read More

The Health 202: Jeff Sessions wants to put more cops on the opioid beat. Experts say that won't solve the problem.

The Washington Post, November 30, 2017
Paige Winfield Cunninghamm, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: If the opioid epidemic was simply a problem of supply – people being able to access drugs too easily – than a targeted new effort in Appalachia announced by Attorney General Jeff Sessions yesterday would be a…

Read More

FDA-Approved Digital Pill Causes Concerns

KJZZ Radio, November 28, 2017
Steve Goldstein, interviewing I. Glenn Cohen (Faculty Director)

The first so-called digital pill has been approved by the Food and Drug Administration. It’s a version of the antipsychotic drug Abilify and contains a tiny sensor that will send a signal to a patch the user is wearing. Advocates say the digital version will keep patients from forgetting…

Read More

Digital pill offers chance of new life to old drugs

Financial Times, November 22, 2017
FT Staff, quoting I. Glenn Cohen (Faculty Director)

From the article: Amid broader concerns about how medical information may be used, Proteus says that its product complies with “all applicable laws and standards” on data protection. Patients can turn off…

Read More

Harvard Forum: Should Older Politicians And Judges Be Tested For Mental Decline?

WBUR, November 17, 2017
Carey Goldberg, describing the "Dementia and Democracy" event

This article describes the event "Dementia and Democracy: America's Aging Judges and Politicians," held on November 15, 2017 at Harvard Law School. 

Read More

A patent ploy: Allergan’s unusual legal tactic attracts political scrutiny

The Economist, November 16, 2017
Economist Staff, citing Rachel E. Sachs (Academic Fellow Alumna)

From the article: [...] The Mohawk tribe argues that it should be treated the same as a state institution. State universities have used sovereign immunity to dismiss challenges brought to the Patent Trial and Appeal Board (PTAB), which conducts patent reviews.…

Read More

First Digital Pill Approved to Worries About Biomedical ‘Big Brother’

New York Times, November 13, 2017
Pam Belluck, featuring I. Glenn Cohen (Faculty Director)

For the first time, the Food and Drug Administration has approved a digital pill — a medication embedded with a sensor that can tell doctors whether, and when, patients take their medicine. The approval, announced late on Monday, marks a significant advance in the growing field of digital…

Read More

Ohio’s Drug-Pricing Ballot Question Triggers Voter Confusion

Kaiser Health News, November 7, 2017
By Shefali Luthra, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Drug pricing is complex and already has caused head-scratching among policymakers and academics, noted Rachel Sachs, an associate professor…

Read More

7 ways biopharma would win — and lose — under the new tax bill

STAT News, November 2, 2017
Rebecca Robbins, citing Rachel E. Sachs (Academic Fellow Alumna)

From the article: [...] The drug industry has fiercely defended this tax credit in the past, calling it essential to encourage investment in disease areas where patients have few options — even as it has come under attack from…

Read More

Dickinson Law Professors Named 2017 Health Law Scholars

Penn State Dickinson Law, October 16, 2017
Featuring Matthew J.B. Lawrence (Academic Fellow Alumnus)

From the article: Medha Makhlouf, assistant professor of law and director, Medical-Legal Partnership Clinic, and Matthew J.B. Lawrence, assistant professor of law, were named 2017 Health Law Scholars at the American Society of Law, Medicine & Ethics’…

Read More

Desperate Quest For Herpes Cure Launched ‘Rogue’ Trial

Kaiser Health News, October 19, 2017
Marisa Taylor, quoting Holly Fernandez Lynch (Former Executive Director, Academic Fellow Alumna)

From the article: As 20 Americans and Brits flew to a Caribbean island for a controversial herpes vaccine trial, many of them knew there were risks. The lead U.S. researcher, William Halford, openly acknowledged he was flouting Food…

Read More

Medicaid’s Best-Price Rule May Not Be Such a Big Problem

Physician's Weekly, October 23, 2017
Physician's Weekly, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Rachel Sachs, J.D., M.P.H., from Washington University in St. Louis, and colleagues discussed Medicaid’s “best-price rule” and the extent to which it might frustrate the goal of paying for value. According to the rule, a pharmaceutical…

Read More

Allergan ruling casts doubt on tribal patent strategy

Reuters, October 17, 2017
Jan Wolfe, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: The company said the PTAB proceeding should be terminated because the tribunal did not have jurisdiction over the tribe. Allergan said it wanted to avoid defending the patent in both federal court and before PTAB. 

Read More

One of Allergan’s blockbuster drugs was dealt a major legal blow

Business Insider, October 16, 2017
Lydia Ramsey, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: Native American tribes, along with institutions like universities, have sovereign immunity that protects patents from certain challenges to their validity.  The tribe, in the Allergan press release, said…

Read More

Judge invalidates Allergan patents and criticizes deal with the Mohawks

STAT, October 16, 2017
Ed Silverman, quoting Rachel E. Sachs

From the article: In a blow to Allergan (AGN), a federal judge invalidated the patents on its Restasis eye treatment, the latest twist in a captivating controversy over the fate of the best-selling medicine. The ruling brings some…

Read More

Court Finds Restasis Patents Invalid, Raises Concerns About Allergan, Mohawk Tribe Agreement

RAPS, October 16, 2017
Zachary Brennan, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: In an 11-page order separate from the one invalidating the Restasis patents for obviousness, US Circuit Judge William Bryson wrote that the court "has serious concerns about the legitimacy of the tactic that Allergan and the Tribe have employed.…

Read More

Ohio Issue 2 ballot initiative proponents overstate impact on EpiPen prices

Politifact, October 13, 2017
Manuela Tobias, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: In addition to the Medicaid program, the state purchases drugs for state employees, prisons, and other state-run programs, but the campaign was unable to pin down the effect of the initiative on these groups. Dennis Willard, a campaign spokesman,…

Read More

Battle over drug prices shifts back to the states

The Hill, October 11, 2017
By Rachel Roubein, quoting Rachel E. Sachs (Academic Fellow Alumna)

From the article: President Trump has derided pharmaceutical companies as “getting away with murder,” but there’s been little action in Washington to rein in the costs of prescription drugs. Some states are taking…

Read More

Congress keeps the heat on 340B

Politico, October 10, 2017
By Sarah Karlin-Smith, citing work by Rachel E. Sachs (Academic Fellow Alumna)

From the article: The House Energy and Commerce Oversight Subcommittee will probe Wednesday into how hospitals and health clinics participating in the 340B discount drug program are using the savings they reap. Nonprofit hospitals and safety net providers…

Read More